A process for forming a hyaluronan hydrogel, comprising the steps of a. providing an aqueous solution comprising i. a first hyaluronan peptide conjugate comprising transglutaminase donor peptides and ii. a second hyaluronan peptide conjugate comprising transglutaminase acceptor peptides, wherein said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate are each represented by a general formula I, wherein 5% to 20%, particularly 8-12%, more particularly approximately 10% of R 1 moieties are represented by a general formula II, wherein - L is NH-Alk or O-Alk or NH-NH-CO-Alk with Alk being a C1 to C5 alkyl, and - Pep is a transglutaminase donor peptide or a transglutaminase acceptor peptide, respectively, and the rest of R 1 moieties are represented by -COOH. b. adding a transglutaminase capable of covalently linking said transglutaminase donor peptides to transglutaminase acceptor peptides to said aqueous solution, wherein the concentration of the sum of said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate is 0.25% (w/v) to 5% (w/v) and wherein said hyaluronan is characterized by a mean molecular weight equal or greater than (≥) 250 kg/mol, and wherein a. the transglutaminase donor peptide sequence is or comprises a sequence selected from SEQ ID NO 01 to SEQ ID 14; b. the transglutaminase acceptor peptide sequence is or comprises a sequence selected from SEQ ID NO 15 to SEQ ID 29. a. providing an aqueous solution comprising i. a first hyaluronan peptide conjugate comprising transglutaminase donor peptides and ii. a second hyaluronan peptide conjugate comprising transglutaminase acceptor peptides, wherein said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate are each represented by a general formula I, wherein 5% to 20%, particularly 8-12%, more particularly approximately 10% of R 1 moieties are represented by a general formula II, wherein - L is NH-Alk or O-Alk or NH-NH-CO-Alk with Alk being a C1 to C5 alkyl, and - Pep is a transglutaminase donor peptide or a transglutaminase acceptor peptide, respectively, and the rest of R 1 moieties are represented by -COOH. i. a first hyaluronan peptide conjugate comprising transglutaminase donor peptides and ii. a second hyaluronan peptide conjugate comprising transglutaminase acceptor peptides, wherein said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate are each represented by a general formula I, wherein 5% to 20%, particularly 8-12%, more particularly approximately 10% of R 1 moieties are represented by a general formula II, wherein - L is NH-Alk or O-Alk or NH-NH-CO-Alk with Alk being a C1 to C5 alkyl, and - Pep is a transglutaminase donor peptide or a transglutaminase acceptor peptide, respectively, and the rest of R 1 moieties are represented by -COOH. wherein said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate are each represented by a general formula I, wherein 5% to 20%, particularly 8-12%, more particularly approximately 10% of R 1 moieties are represented by a general formula II, wherein - L is NH-Alk or O-Alk or NH-NH-CO-Alk with Alk being a C1 to C5 alkyl, and - Pep is a transglutaminase donor peptide or a transglutaminase acceptor peptide, respectively, and the rest of R 1 moieties are represented by -COOH. - L is NH-Alk or O-Alk or NH-NH-CO-Alk with Alk being a C1 to C5 alkyl, and - Pep is a transglutaminase donor peptide or a transglutaminase acceptor peptide, respectively, and the rest of R 1 moieties are represented by -COOH. b. adding a transglutaminase capable of covalently linking said transglutaminase donor peptides to transglutaminase acceptor peptides to said aqueous solution, wherein the concentration of the sum of said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate is 0.25% (w/v) to 5% (w/v) and wherein said hyaluronan is characterized by a mean molecular weight equal or greater than (≥) 250 kg/mol, and wherein a. the transglutaminase donor peptide sequence is or comprises a sequence selected from SEQ ID NO 01 to SEQ ID 14; b. the transglutaminase acceptor peptide sequence is or comprises a sequence selected from SEQ ID NO 15 to SEQ ID 29. wherein the concentration of the sum of said first hyaluronan peptide conjugate and said second hyaluronan peptide conjugate is 0.25% (w/v) to 5% (w/v) and wherein said hyaluronan is characterized by a mean molecular weight equal or greater than (≥) 250 kg/mol, and a. the transglutaminase donor peptide sequence is or comprises a sequence selected from SEQ ID NO 01 to SEQ ID 14; b. the transglutaminase acceptor peptide sequence is or comprises a sequence selected from SEQ ID NO 15 to SEQ ID 29.